IM Cannabis Corp.
IM Cannabis is an international medical cannabis company focused on importing, distributing and selling products to medical patients in Israel and Germany. Its operations include medical cannabis pharmacies, online retail and home delivery in Israel, as well as distribution to licensed pharmacies in Germany through its subsidiary Adjupharm. The company also maintains proprietary cannabis genetics through third-party cultivation facilities in Israel and operates a German logistics and processing facility that provides repackaging, stability testing and batch release services. IM Cannabis sells dried cannabis flowers and full-spectrum extracts under brands including IMC, Roma, Selected by IMC and BLKMKT, alongside licensed third-party products. It makes money primarily by selling medical cannabis products, and also offers services such as processing and testing. Its principal executive offices are in Kibbutz Glil Yam, Israel.
No enriched coverage for $IMCC in the last 7 days.
No SEC Form 4 filings for $IMCC in the last 30 days.
See all $IMCC insider activity →IM Cannabis Corp. (Nasdaq: IMCC) raised US$1.2M in a convertible note financing from an existing institutional investor. The note bears 4% interest, matures in 28 months, and is convertible into common shares at a price of up to US$0.610 per share. The company issued warrants for 3.9M shares and plans to use proceeds for general corporate purposes.
Invest Pro Shukai Hon Ltd. reported a 9.99% stake in IM Cannabis Corp. (IMCC), owning 164,585 common shares with sole voting and dispositive power. The ownership percentage is based on 1,647,494 issued and outstanding shares, as provided by the company. Eli Zamir, a director, signed the filing.
IM Cannabis Corp. (IMCC) announced that Einat Zakariya resigned from the board and committees for personal reasons. The company operates medical cannabis platforms in Israel and Germany, with plans to sell I.M.C. Holdings Ltd.
Recent IMCC coverage spans corporate actions, financial news and mergers & acquisitions.
The financing provides short‑term cash but introduces dilution risk, likely leading to modest price pressure.
The filing reveals a sizable shareholder stake, which may influence future corporate decisions.
The resignation may raise concerns about board stability and could weigh on the stock.
Modest capital infusion to support working capital; limited upside for price.
The capital raise dilutes existing shareholders and the pending acquisition adds execution risk, supporting further downside.
AlphAI scores every news story that mentions IMCC with an AI model for sentiment and relevance, and aggregates insider trades from IM Cannabis Corp.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
IM Cannabis Corp. (Nasdaq: IMCC) raised US$1.2M in a convertible note financing from an existing institutional investor. The note bears 4% interest, matures in 28 months, and is convertible into common shares at a price of up to US$0.610 per share. The company issued warrants for 3.9M shares and plans to use proceeds for general corporate purposes.
Invest Pro Shukai Hon Ltd. reported a 9.99% stake in IM Cannabis Corp. (IMCC), owning 164,585 common shares with sole voting and dispositive power. The ownership percentage is based on 1,647,494 issued and outstanding shares, as provided by the company. Eli Zamir, a director, signed the filing.
IM Cannabis Corp. (IMCC) announced that Einat Zakariya resigned from the board and committees for personal reasons. The company operates medical cannabis platforms in Israel and Germany, with plans to sell I.M.C. Holdings Ltd.
IM Cannabis Corp. (IMCC) closed a registered direct offering, selling 655,000 common shares at $2.00 each, raising $1.31M. Proceeds will be used for working capital and potential business opportunities. A related party transaction involved Invest-Pro, a company led by a director of IMCC, purchasing 164,585 shares.
IM Cannabis (IMCC) shares fell 25.85% after announcing a $1.31M share offering and a non-binding deal to acquire 51% of Space Defense Innovations, expanding into defense technology. The acquisition, if completed, would be funded with shares, warrants, and a loan. IM Cannabis operates medical cannabis businesses in Israel and Germany.
IM Cannabis Corp (IMCC) shares dropped 18.6% premarket after announcing a $1.31M share offering at a discount. The company cited financial hardship, with proceeds earmarked for working capital and potential opportunities. The offering may include related parties and is set to close by September 24, 2026.
IM Cannabis Corp. (IMCC) has entered a non-binding agreement to acquire 51% of Space Defense Innovations LLC (SDI), a Polish company operating in the unmanned aerial systems (UAS) sector. The deal involves IMCC common shares, pre-funded warrants, and a seller loan. SDI distributes BlueBird Aero Systems' tactical UAS and hybrid fixed-wing VTOL-UAS platforms in Europe.
IM Cannabis (IMCC) surged 245% with no clear catalyst, trading between $2.97 and $8.65. XORTX (XRTX) rose 12% on plans for a 2026 FDA application. Silo Pharma (SILO) gained 6.73% after a U.S. patent allowance. Biofrontera (BFRI) increased 5.65% despite no new news, following an FDA approval for Ameluz.
IM Cannabis Corp. (IMCC) raised US$225,000 through a convertible note financing with an institutional investor. The note bears 8% interest, convertible into common shares at a fixed or market-based price. Proceeds will be used for general corporate purposes. The company also issued warrants for 77,855 shares. IMCC operates in Israel and Germany, with plans to sell its German operations.
IM Cannabis Corp. (IMCC) plans a 30:1 share consolidation by September 15, 2026, to meet Nasdaq's $1.00 minimum bid price requirement. The company expects 603,922 shares post-consolidation, with trading to resume on August 27, 2026. The move aims to regain compliance with Nasdaq's listing rules.
